Array Biopharma (ARRY) Reports Data Presentation On ARRY-797 at ESC Congress
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from a Phase 2 study of ARRY-797 will be presented at the 2016 European Society of Cardiology (ESC) Congress, which will be held August 27 – 31, 2016 in Rome, Italy.
Phase 2 study of A797, an oral, selective p38 mitogen-activated protein kinase inhibitor, in patients with lamin A/C-related dilated cardiomyopathy (Abstract #P4981)
Calum A. MacRae, MD
Tuesday, August 30, 10:19 a.m. CEST
Updated and additional data will be provided at the conference beyond what is included in the abstract.
All abstracts can be accessed through the ESC website, or on this web page: http://spo.escardio.org/default.aspx?eevtid=1127.
The ARRY-797 abstract can be found by clicking this LINK.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mallinckrodt (MNK) Announces FTC Settlement
- Raytheon (RTN) Elects James Winnefeld Jr. to Board of Directors
- CFPB Confirms Suit Against Navient (NAVI) Over Student Loan Repayment